Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 8/20 | 0.46 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.44 |
| ▸ | MET | P08581 | 5/20 | 0.42 |
| ▸ | KDR | P35968 | 3/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4591188 | 0.76 | FGFR2 (0.51) | FGFR2PDGFRAPDGFRB | |
| SCHEMBL371554 | 0.76 | FGFR2 (0.48) | AXLFGFR2KDRPDGFRAPDGFRB | |
| SCHEMBL4565003 | 0.76 | FGFR2 (0.43) | AXLFGFR2METKDRPDGFRA | |
| SCHEMBL6431113 | 0.75 | FGFR2 (0.60) | AXLFGFR2METKDRPDGFRA | |
| SCHEMBL1791452 | 0.72 | PDGFRA (0.52) | FGFR2METKDRPDGFRAPDGFRB | |
| SCHEMBL371541 | 0.70 | MET (0.46) | AXLFGFR2METKDR | |
| SCHEMBL29693528 | 0.70 | MET (0.53) | METKDRPDGFRACSF1RRET | |
| SCHEMBL371600 | 0.70 | MET (0.53) | METKDRPDGFRACSF1RRET | |
| SCHEMBL10242715 | 0.69 | FGFR2 (0.43) | AXLFGFR2METKDRPDGFRA | |
| SCHEMBL408647 | 0.69 | MET (0.45) | AXLFGFR2METKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3329918-B1 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2022-05-25 | — | — | EP | disclosed |
| EP-2210607-A1 | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-piperidin-1-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer | Exelixis Inc. (US) | 2010-07-28 | — | — | EP | disclosed |